Patients with Li-Fraumeni syndrome and mutp53 were reported to have earlier development of tumors compared with those with Li-Fraumeni syndrome and TP53 deletion (Bougeard et al., 2008). This evidence concerns the gene TP53 and Li-Fraumeni syndrome.